全文获取类型
收费全文 | 108篇 |
免费 | 3篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 4篇 |
妇产科学 | 1篇 |
基础医学 | 6篇 |
口腔科学 | 3篇 |
临床医学 | 5篇 |
内科学 | 17篇 |
皮肤病学 | 4篇 |
神经病学 | 3篇 |
特种医学 | 2篇 |
外科学 | 13篇 |
综合类 | 20篇 |
预防医学 | 7篇 |
眼科学 | 5篇 |
药学 | 6篇 |
中国医学 | 13篇 |
肿瘤学 | 3篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 15篇 |
2018年 | 17篇 |
2017年 | 6篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 2篇 |
2013年 | 4篇 |
2012年 | 8篇 |
2011年 | 6篇 |
2010年 | 1篇 |
2009年 | 4篇 |
2008年 | 1篇 |
2006年 | 2篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1991年 | 1篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1979年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有113条查询结果,搜索用时 15 毫秒
1.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404
Background
Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.Methods
A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.Results
Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.Conclusions
Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting. 相似文献2.
3.
Biddle DA Datta P Wells A Dasgupta A 《Clinica chimica acta; international journal of clinical chemistry》2000,300(1-2):151-158
4.
5.
Michael T.B. Nguyen Vishakha Thakrar Clara C. Chan 《Canadian journal of ophthalmology. Journal canadien d'ophtalmologie》2018,53(1):66-70
Objective
To describe indications and outcomes of patients fitted with the EyePrintPRO therapeutic scleral lens.Methods
A database search of patients fitted with the EyePrintPRO from 2014 to 2016. Fourteen eyes of 10 patients were reviewed retrospectively. Patient demographics, medical and ocular history, indications for fitting, duration of wear, symptoms, and best-corrected visual acuity (BCVA) were analyzed.Results
Mean age at lens fitting was 49 years (range, 21–67 years). The average duration of wear was 12 months (range, 7–17 months). Indications for fitting included limbal stem cell deficiency, post–photorefractive keratectomy (PRK) decentred ablation, pellucid marginal degeneration, Stevens-Johnson syndrome, keratoconus, dry eye, neurotrophic keratitis, exposure keratitis from facial nerve paralysis, and post–radial keratotomy (RK) symptoms. Mean BCVA was 20/36 (range, 20/20–20/200). After the fitting, mean BCVA was 20/21 (range 20/10–20/60, p = 0.001). Nine patients reported resolution of their blurry vision, and all reported improvement of dry eye, eye redness, and pain symptoms. Six of 7 previous lens wearers reported significantly greater comfort with EyePrintPRO wear and the ability to wear the lens throughout the day; only 2 experienced fogging and needed to clean the lens after 4–6 hours of wear.Conclusions
A variety of indications for the EyePrintPRO scleral lens exist, and patients experience resolution of major symptoms. The ophthalmologist should be aware that therapeutic scleral lenses, including the EyePrintPRO, exist for patients for whom there is no surgical intervention or who want to delay or obviate the need for surgery. 相似文献6.
7.
目的:探讨禅宗"指月"之喻与《医古文》启发式教学的关系。方法:引述禅宗经典与启发式教学进行比较。结果与结论:禅宗"指月"之喻与《医古文》之启发式教学有异曲同工之妙。 相似文献
8.
目的观察益髓除颤汤加服小剂量左旋多巴和左旋多巴治疗帕金森氏病的疗效。方法采用随机开放对照方法,将60例患者随机按2:1比例分为两组,治疗组40例,用自拟益髓除颤汤加小剂量左旋多巴;对照组20例,单纯用左旋多巴常规治疗,1月为一疗程,3个疗程后评定疗效。结果治疗组总有效率97.50%。对照组85.00%。治疗组明显优于对照组(P<0.05)。两组治疗前后症状、体征对比,治疗组优于对照组(P<0.05),药物副反应治疗组低于对照组。结论自拟益髓除颤汤加小剂量左旋多巴较单纯用左旋多巴治疗帕金森氏病,疗效确切,副作用小,症状缓解快。 相似文献
9.
Dr.Yeh-chong Chan (Y.C.Chan) is one of the earliest acupuncturists in the United States (US).He served for seven years in the first acupuncture center in the US,which was established in Washington,D.C.in 1972.In 1979,he moved the clinic to Rockville,Maryland and continued to practice acupuncture there for over 30 years.He is a well-known licensed acupuncturist (LAc),one of the developers of the acupuncture profession,and a scholar of acupuncture and traditional Chinese medicine (TCM).He has treated two US Governors (In the US,the title Governor refers to the chief executive of each state or insular territory and the political and ceremonial head of the state.) and many sports stars.He is the author of books entitled Acupuncture Practice in the United States [1],Dr.Chan's Cancer Healing,Prevention and Self-healing and others.To record the early history of acupuncture in the US,on September 30,2012,the author,Dr.Arthur Fan interviewed Dr.Chan,70 years old,who is still in practice. 相似文献
10.
[ 目的]《百济新集方》是东医最古医学文献之一.其方两首出自日本·丹波康赖撰《医心方》.本文就界定其问世年代为目的.[ 方法]《医心方》录有的《百济新集方》分别为黄耆治肺痈方、菊花治疔肿毒气入心欲困死方.在中医文献中考察这两首方,并以究其传播到百济的年代的方法进行.[ 结果]《医心方》所录《百济新集方》的两首方,均是《肘后方》的基础上产生的方.梁·大同七年,百济遣使梁求过经疏及医工.梁代有《肘后方》等132 种医书.[ 结论]《百济新集方》问世年代,是相当于梁·大同七年至隋开国之前的百济圣王明衤农十九年( 公元541 年) 至威得王昌二十七年( 公元580 年) 间. 相似文献